Odyssey Therapeutics is a clinical-stage biotechnology company developing precision medicines for autoimmune and inflammatory diseases. Its pipeline combines small-molecule and protein therapeutics aimed at selective targets in inflammatory signaling pathways. Lead programs address areas of high unmet need in immunology, including inflammatory bowel disease, rather than commercial marketed products today.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q4 2024 | 1.8 | — | -36.8 | — |
| Q1 2025 | 1.9 | — | -38.4 | — |
| Q2 2025 | 1 | — | -41.2 | — |
| Q1 2026 | 0 | -100% | -38.3 | — |
| Q2 2026 | 0 | -100% | -52.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Marten Transport, Ltd. (MRTN), Red Violet, Inc. (RDVT), National Healthcare Properties, Inc. (NHP), Prospect Capital Corporation (PSEC), Heritage Financial Corporation (HFWA), Oaktree Specialty Lending Corporation (OCSL)